From The Stage

Ligand-Binding Assay Optimization, Part 1: Critical Attributes of Platforms Used

Dr. Afshin Safavi
Posted by Dr. Afshin Safavi / / Bioanalytical Platforms

Consistent discussion and improvement upon the standard practices of bioanalytical laboratories is critical to improving the work we do supporting innovative biologics development in the long-term. One of the rapidly advancing areas that is being regularly discussed in the industry is the evolution of ligand-binding assay (LBA) platforms. In this blog, I will summarize best practices and characteristics associated with LBA platforms as well as the features these platforms absolutely need to enable scientists to respond to industry pressures that drive demand for increasingly complex bioanalysis, condensed timelines, and continued…

Setting Yourself Up for Success: Advice for Early Career Scientists

Dr. Afshin Safavi
Posted by Dr. Afshin Safavi / / BioAgilytix Insight

Having been in the pharmaceutical and biotechnology industry for more than two decades – in roles spanning from R&D to manufacturing, for both small and large organizations – I have gained a unique perspective that I hope can provide helpful insight to young science major graduates before and after they enter the workforce.

Evaluation of CAR T-Cell Therapy Toxicities by Measurement of Cytokines During Therapy

Dr. Afshin Safavi
Posted by Dr. Afshin Safavi / / Immuno-oncology

T cells can be genetically modified to target tumors through the expression of a chimeric antigen receptor (CAR). CAR-T cells have demonstrated clinical efficacy in hematologic malignancies and targeting solid tumors. However, CAR-T therapy also can elicit cytokine release syndrome (CRS) cytotoxicity. This unwanted release of cytokines has also been seen following the infusion of therapeutic monoclonal antibodies (mAbs), systemic interleukin-2 (IL-2), and the bispecific CD19-CD3 T-cell engaging antibody blinatumomab.

Key Takeaways from the 12th Workshop on Recent Issues in Bioanalysis (WRIB)

Dr. Afshin Safavi
Posted by Dr. Afshin Safavi / / BioAgilytix Insight, Industry Update

Scientists from BioAgilytix recently attended the 12th WRIB in Philadelphia, PA. Meeting new contacts in the industry and taking part in discussions concerning the most innovative topics in bioanalysis, biomarkers, and immunogenicity was a genuinely valuable and enjoyable experience. We recap the topics that our team found to be most interesting at WRIB this year.